Navigation Links
BioMed Realty Trust Announces Retirement of Mark Riedy From Its Board of Directors
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that Mark Riedy will retire from its board of directors concurrently with the company's annual meeting of stockholders, scheduled for May 21, 2008.

Dr. Riedy, the Ernest W. Hahn Professor of Real Estate Finance and Executive Director of the Burnham-Moores Center for Real Estate at the University of San Diego, has been a member of the company's board of directors since its initial public offering in 2004, and also served as a member of the board's compensation committee and as past chair and current member of the board's audit committee.

"We are thankful for all of Mark's valuable contributions to BioMed over the past four years," said Alan Gold, President and Chief Executive Officer of BioMed Realty Trust. "During his tenure, BioMed has grown from 13 properties, representing an aggregate of 2.3 million rentable square feet, at its initial public offering in 2004 to 68 properties, representing 8.5 million rentable square feet and 1.9 million square feet of development in progress, which are positioned in some of the country's most sought-after locations for life science space. His insight and experience have helped advance BioMed to where it is today, with the solid financial and operational foundation upon which we will continue to execute on our mission of being the leading provider of real estate to the life science industry."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 68 properties, representing 104 buildings with approximately 8.5 million rentable square feet, as well as approximately 1.9 million square feet of development in progress. These properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at http://www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
2. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
3. BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend
4. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
5. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
6. LifeNet Health(R) Unveils New Biomedical Spine Implant
7. MIT researcher addresses biomedical engineering challenges
8. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
9. BioMed Realty Trust Announces Tax Treatment of 2007 Distributions
10. BioMed Realty Trust To Report 2007 Fourth Quarter and Year-End Results
11. Bookham to Enter Biomedical Illumination Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/22/2016)... 2016 Cell Applications, Inc. and StemoniX ... produce up to one billion human induced pluripotent ... week. These high-quality, consistent stem cells enable researchers ... spend more time doing meaningful, relevant research. This ... manufacturing process that produces affordable, reliable HiPSC for ...
(Date:6/22/2016)... Philadelphia, PA (PRWEB) , ... June 22, 2016 ... ... the University City Science Center’s Port business incubator and current participant in the ... therapy and treatment for cancer patients. , Quantitative Radiology Solutions helps physicians ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... that has developed a testing platform designed specifically ... the formation of their scientific advisory board (SAB). ... of directors, the SAB is chartered to advise ... infectious disease assay platform. Led by Dr. ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):